^
Association details:
| Biomarker: | CD44 underexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | TheraCIM (nimotuzumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab
Published date:
02/09/2022
Excerpt:
Pretreatment tumour tissues of 404 HPV-negative LA-HNSCCs patients, a subset of-phase 3-randomised study comparing cisplatin-radiation(CRT) and nimotuzumab plus cisplatin-radiation(NCRT) were examined.....NCRT showed significantly improved OS with low membrane expression of CD44 compared to CRT [HR (95% CI) = 0.63 (0.46-0.88)]....CD44 and CD44v6 are potential predictive biomarkers for NCRT response.
DOI:
10.1038/s41416-022-01730-9
